

IN THE CLAIMS

Please amend the claims as follows:

Claims 1-8 (Canceled).

Claim 9 (New): A medicinal composition comprising an insulin resistance-improving drug, and vitamin B₁ or derivative thereof.

Claim 10 (New): The medicinal composition claimed in Claim 9, comprising 5 to 300 mg of insulin resistance-improving drug, and 1 to 500 mg of vitamin B₁ or derivative thereof for one unit dose.

Claim 11 (New): A medicinal composition claimed in Claim 9, wherein the insulin resistance-improving drug has a γ -agonist activity of peroxisome proliferator-activated receptor.

Claim 12 (New): A medicinal composition claimed in Claim 9, wherein the insulin resistance-improving drug is a thiazolidine-type compound having a γ -agonist activity of peroxisome proliferator-activated receptor.

Claim 13 (New): A medicinal composition claimed in Claim 9, wherein the insulin resistance-improving drug is pioglitazone, rosiglitazone or CS-011, or a salt thereof.

Claim 14 (New): A medicinal composition claimed in Claim 9, wherein the insulin resistance-improving drug is a non-thiazolidine-type compound having a γ -agonist activity of peroxisome proliferator-activated receptor.

Claim 15 (New): A medicinal composition claimed in Claim 9, wherein the insulin resistance-improving drug is TAK-559 or FK-614, or salt thereof.

Claim 16 (New): A medicinal composition claimed in Claim 9, being used for prevention of a side effect selected from edema, hear enlargement and anemia.